Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer-Reference-Cited by-同舟云学术

Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer

Published:2020-01-29 Issue:3 Volume:63 Page:129-143
ISSN:0362-4803
Container-title:Journal of Labelled Compounds and Radiopharmaceuticals
language:en
Short-container-title:J Label Compd Radiopharm

Author:

Stenberg Vilde Yuli¹²³^ORCID,Juzeniene Asta¹^ORCID,Chen Qingqi⁴^ORCID,Yang Xiaoming⁴^ORCID,Bruland Øyvind Sverre³⁵^ORCID,Larsen Roy Hartvig²

Affiliation:

1. Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital; Oslo University Hospital; Oslo Norway

2. Department of Research and Development; Nucligen AS; Oslo Norway

3. Institute for Clinical Medicine; University of Oslo; Oslo Norway

4. Department of Drug Synthesis; MedKoo Biosciences; Morrisville North Carolina

5. Department of Oncology, Norwegian Radium Hospital; Oslo University Hospital; Oslo Norway

Funder

Norges Forskningsråd

Nucligen AS

Sciencons AS

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Radiology Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jlcr.3825/fullpdf

Reference56 articles.

1. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis;Hupe;Front Oncol,2018

2. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer;Paschalis;Eur Urol,2019

3. Targeted alpha-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine;Chakravarty;Am J Nucl Med Mol Imaging,2018

4. New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen;Cimadamore;Front Oncol,2018

5. PSMA ligands in prostate cancer-probe optimization and theranostic applications;Lutje;Methods,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective;Cancers;2024-04-25

2. Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals;Frontiers in Chemistry;2024-02-08

3. Tuning the Softness of the Pendant Arms and the Polyazamacrocyclic Backbone to Chelate the ²⁰³Pb/²¹²Pb Theranostic Pair;Inorganic Chemistry;2024-01-17

4. Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

5. Influence of the Molar Activity of 203/212Pb-PSC-PEG2-TOC on Somatostatin Receptor Type 2-Binding and Cell Uptake;Pharmaceuticals;2023-11-14